A Study to Evaluate the Efficacy and Safety of Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Inclusion Criteria:

• Biopsy-proven primary FSGS or primary MCD.

• UPCR ≥3 g/g at screening.

• eGFR ≥45 mL/min/1.73 m^2 at screening.

• Documented history of UPCR reduction by ≥40% in response to corticosteroid or otherimmunosuppressive therapy when pre-treatment UPCR was ≥3.5 g/g.

• ≤10 mg/day prednisone or equivalent and stable starting at least 1 week prior torandomization.

• On stable dose of RAAS inhibitors for ≥4 weeks prior to screening (if applicable);starting RAAS inhibitors treatment will not be allowed during the double-blind orOLE treatment period.

• On stable dose of SGLT2 inhibitor for ≥4 weeks prior to screening (if applicable);starting SGLT2 inhibitor treatment will not be allowed during the double-blind orOLE treatment periods.

• Body weight within 45 to 120 kg (inclusive) at screening.

Exclusion Criteria:

• Genetic or secondary FSGS or MCD. Those with APOL1 risk alleles are eligible.

• Collapsing variant of FSGS.

• ESKD requiring dialysis or transplantation.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.